Venous Thromboembolic Complications in Patients with Coronavirus Diseases 2019 Infection Hospitalized in the Infectious and Tropical Diseases Department of CHNU de FANN in Dakar

Ndéye Fatou Ngom^{1, 2,} , Awa Ba^{1, 3}, Khardiata Diallo^{4, 5}, Lamyae Nadif⁴, Maguette Fall⁴, Alassane Ndiaye^{1, 6}, Fulgence Abdou Faye^{1, 3}, Daye Ka^{4, 5}, Oousseynou Ka^{6, 7} and Moussa Seydi^{4, 5}

¹Department of Medicine, UFRSDD, Alioune Diop University, Bambey

²Outpatient Treatment Center, Fann Hospital, Dakar;Hospital Heinrich Lucke, Diourbel

³Hospital Heinrich Lucke, Diourbel

⁴Infectious Diseases Department, Fann Hospital, Dakar

⁵Cheikh Anta Diop University, Dakar

⁶Outpatient Treatment Center, Fann Hospital, Dakar

⁷Department of community health, UFRSDD, Alioune Diop University, Bambey

Cite this paper:
Ndéye Fatou Ngom, Awa Ba, Khardiata Diallo, Lamyae Nadif, Maguette Fall, Alassane Ndiaye, Fulgence Abdou Faye, Daye Ka, Oousseynou Ka and Moussa Seydi. Venous Thromboembolic Complications in Patients with Coronavirus Diseases 2019 Infection Hospitalized in the Infectious and Tropical Diseases Department of CHNU de FANN in Dakar. American Journal of Infectious Diseases and Microbiology. 2025; 13(3):44-50. doi: 10.12691/ajidm-13-3-1

Abstract

Introduction: Coronavirus Disease 2019 (COVID-19) is caused by SARS-CoV-2. High rates of venous thromboembolic disease (VTE) are reported in COVID-19, correlating with severe disease and unexplained deaths. This study aimed to characterize VTE development and associated factors in COVID-19 patients hospitalized at SMIT from January to December 2021. Materials and methods: We conducted a retrospective, descriptive, and analytical study of COVID-19 patients with VTE hospitalized at the SMIT, CHNU Fann, Dakar, from January to December 2021. Results: Among 248 hospitalized COVID-19 patients over 12 months, 12 developed VTE, a frequency of 4.84%. Patients were predominantly male (66.67%, sex ratio 1.25) with a mean age of 50.57 years (28-74). Common comorbidities included hypertension, diabetes (both 33.33%), and smoking (25%). RT-PCR was positive in 7 patients, and all 4 patients tested for D-dimer had elevated levels. All patients received corticosteroids and anticoagulation. Antiasthenic were administered in 11 patients, and antibiotics in 10. Only two patients had received a dose of COVID-19 vaccine. The average hospital stay was 10.82 days, with extremes of 1 and 25 days. Smoking was the only significant factor associated with thromboembolic complications. The case fatality rate was 33.33%. Conclusion: Venous thromboembolic complications are common in COVID-19, emphasizing the critical role of COVID-19 prevention. frequent in COVID-19 disease, hence the importance of prevention against COVID-19.

Keywords:
COVID-19 venous thromboembolic complication SMIT Senegal

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Pan African Health Organization (PAHO), (WHO) WHO. WHO declares Public Health Emergency on novel coronavirus. 2020. [Consulted le 17/02/25]. Available on: https:// en/news/ 30-1- 2020-who-declares-public-health-emergency-novel-coronavirus.
[2]	World Health Organization (WHO). WHO COVID-19 dashboard. 2025. [Consulted le 17/02/2025]. Available on: https://data.who.int/dashboards/covid19/cases?n=c.
[3]	Ministere de la Sante et de l’Action Sociale (MSAS). Infection au Covid-19 et risque thromboembolique: prise en charge au Senegal. 2020. [Consulted le 17/02/2025]. Available on: https://sosear.org/wp-content/uploads/2022/08/INFECTION-AU-COVID-19-ET-RISQUE-THROMBOEMBOLIQUE-V2.pdf.
[4]	Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020; 7(6): e438-e40.
[5]	Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395 (10223): 497–506.
[6]	Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99cases of2019novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223): 507–513.
[7]	Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020; 191: 145-7.
[8]	Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. New England Journal of Medicine. 2020; 382(8): 727-33.
[9]	Zuin M, Engelen MM, Barco S, Spyropoulos AC, Vanassche T, Hunt BJ, et al. Incidence of venous thromboembolic events in COVID-19 patients after hospital discharge: A systematic review and meta-analysis. Thromb Res. 2022;209:94-8.
[10]	Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020; 395(10229): 1054-62.
[11]	Argenziano MG, Bruce SL, Slater CL, Tiao JR, Baldwin MR, Barr RG, et al. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. BMJ. 2020; 369: m1996.
[12]	Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastian T, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thrombosis Research. 2020; 191: 9-14.
[13]	Ivala Mendome Y, Kinga A, Tchikaya Thickinson Y, Andemey Leyoubou E. Epidemiological and clinical aspects of thrombotic manifestations during COVID-19 in the military hospitals of Libreville and Akanda, Gabon. Rev anesth-réanim med urgence. 2023,: 138-43.
[14]	Poissy J., Goutay, J., Caplan, M., Parmentier, E., Duburcq, T., Lassalle, F., Jeanpierre E., Rauch A., et al. COVID-19 and Pulmonary Embolism. Circulation. 2020; 142: 184–186.
[15]	A. Trimaille, G. Bonnet, Annals of Cardiology and Angiology 69 (2020) 370–375.
[16]	World Health Organization (WHO). Naming the coronavirus disease (COVID-19) and the virus that causes it. 2020. [Consulted le 17/02/2025]. Available on: https:// emergencies/ diseases/ novel-coronavirus-2019/ technical-guidance/ naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it.
[17]	White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107(23 Suppl 1): I4-8.
[18]	Roseann Andreou E, Koru‐Sengul T, Linkins L, Bates SM, Ginsberg JS, Kearon C. Differences in clinical presentation of deep vein thrombosis in men and women. Journal of Thrombosis and Haemostasis. 2008; 6(10): 1713-9.
[19]	Poissy J, Goutay J, Caplan M, Parmentier E, Duburcq T, Lassalle F, et al. Pulmonary Embolism in Patients With COVID-19: Awareness of an Increased Prevalence. Circulation. 2020; 142(2): 184-6. 17 66.
[20]	Bouaziz M, Koubaa M, Fekih M, et al. Thrombotic and thromboembolic events in COVID-19 patients: Incidence, risk factors, and prognosis. Pan Afr Med J. 2022;43:123. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9836888/.
[21]	Porfidia A, Valeriani E, Pola R, Porreca E, Rutjes AWS, Di Nisio M. Venous thromboembolism in patients with COVID-19: Systematic review and meta-analysis. Thromb Res. 2020; 196: 67-74.
[22]	Berger, J. S., Kunichoff, D., Adhikari, S., Ahuja, T., Amoroso, N., Aphinyanaphongs, Y., Cao, M., Goldenberg, R., Hindenburg, A., Horowitz, J., Parnia, S., Petrilli, C., Reynolds, H., Simon, E., Slater, J., Yaghi, S., Yuriditsky, E., Hochman, J., & Horwitz, L. I. (2020). Prevalence and Outcomes of D-Dimer Elevation in Hosp
[23]	Mahsouli A, Grillo M, Amini N, Acid S, Coche E, Ghaye B. Imagerie thoracique du COVID-19. Louvain Med. 2020;139(05-60): 360-7.
[24]	Léonard-Lorant I, Delabranche X, Séverac F, Helms J, Pauzet C, Collange O, et al. Acute Pulmonary Embolism in Patients with COVID-19 at CT Angiography and Relationship to d-Dimer Levels. Radiology. 2020; 296(3): E189-e91.
[25]	Planquette B, Le Berre A, Khider L, et al. Prevalence and risk factors of venous thromboembolism in COVID-19 patients hospitalized in medical wards: The French COVID cohort study. Thromb Res. 2021; 204: 24-29.
[26]	Patell R, Bogue T, Koshy A, Bindal P, Merrill M, Aird WC, Bauer KA, Zwicker JI. Incidence of thrombosis and hemorrhage in hospitalized cancer patients with COVID-19. J Thromb Haemost. 2020; 18(9): 2349-2357.
[27]	Minet C, Potton L, Bonadona A. et al. Venous thromboembolism in the ICU: main characteristics, diagnosis and thromboprophylaxis. Crit Care 2015; 19(01): 287.